NanoViricides Inc(NNVC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.41 | Insider Own | 2.49% | Shs Outstand | 25.5M | Perf Week | 10.77% |
| Market Cap | 0.04B | Forward P/E | 2.88 | EPS next Y | 208.7% | Insider Trans | - | Shs Float | 24.9M | Perf Month | 33.33% |
| Enterprise Value | 0.03B | PEG | - | EPS next Q | -0.1 | Inst Own | 9.29% | Short Float | 2.36% | Perf Quarter | -10.56% |
| Income | -0.01B | P/S | - | EPS this Y | -6.98% | Inst Trans | 1.98% | Short Ratio | 1.31 | Perf Half Y | 30.91% |
| Sales | 0.00B | P/B | 3.82 | EPS next 5Y | - | ROA | -87.91% | Short Interest | 0.59M | Perf YTD | 27.43% |
| Book/sh | 0.38 | P/C | 13.17 | EPS past 3/5Y | 18.01% 12.84% | ROE | -101.46% | 52W High | -35.42% ($2.23) | Perf Year | 1.41% |
| Cash/sh | 0.11 | P/FCF | - | Sales past 3/5Y | - | ROIC | -94.65% | 52W Low | 69.41% ($0.85) | Perf 3Y | 10.77% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 35.47% | Gross Margin | - | Volatility(W/M) | 8.46% 10.41% | Perf 5Y | -67.35% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.13 | Perf 10Y | -95.5% |
| Dividend Ex-Date | - | Quick Ratio | 2.66 | EPS Q/Q | 21.51% | Profit Margin | - | RSI (14) | 55.53 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.66 | Sales Q/Q | - | SMA20 | 7.87% ($1.33) | Beta | 1.84 | Target Price | $6 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/09/02 | SMA50 | 8.16% ($1.33) | Rel Volume | 0.68 | Prev Close | $1.4 |
| Employees | 7 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -10% - | SMA200 | 13.01% ($1.27) | Avg Volume(3M) | 0.45M | Price | $1.44 |
| IPO | 2004/8/12 | Option/Short | Yes/No | Trades | 660 | Volume | 306,219 | Change | 2.86% |
Nanoviricides (NNVC) is a clinical-stage biotech developing broad-spectrum antivirals that combine nanotechnology with a host-mimetic strategy. Its lead candidate, NV-387, has entered Phase II clinical trials targeting MPox (monkeypox) and respiratory viruses, and NV-HHV-1 for shingles is also part of the pipeline.
Over the past 1 year, roughly in the middle
35% below its 1-year high.
Traded less than usual That is 68% of its average volume.
NNVC has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -7.0% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -67.3%. The S&P 500 did +77% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 9.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #446 of 592 in the industry
Based on market cap of $37M.
LITS#442 Lite Strategy Inc $39M PER - 
IBO#443 Impact BioMedical Inc $38M PER - 
CVM#444 Cel-Sci Corp $37M PER - 
MGX#445 Metagenomi Therapeutics Inc $37M PER - NNVC#446 NanoViricides Inc $37M PER - 
FAQ
What kind of company is NNVC?
NNVC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NNVC?
The market cap of NNVC is approximately $37M, ranking 5,062 within its sector.
What is the 52-week high and low for NNVC?
NNVC has recorded a 52-week high of $2.23 and a low of $0.85.
